参考文献/References:
[1] James PA, Oparil S, Carter BL, et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC 8)[J]. JAMA,2014,311(5): 507-520.
[2] Joffres MF, Gillespie C, Robitaille C,et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality:a cross-sectional study[J]. BMJ Open,2013,3(8):e003423.
[3] Calhoun DA, Jones D, Textor S,et al.Resistant hypertension:diagnosis, evaluation, and treatment:a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J].Circulation,2008,117(25):e510-e526.
[4] Calhoun DA, Booth JN, Oparil S,et al. Refractory hypertension:determination of prevalence,risk factors,and comorbidities in a large,population-based cohort[J]. Hypertension,2014,63(3):451-458.
[5] Sierra A, Segura J, Banegas JR, et al.Clinical features of 8 295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring[J]. Hypertension,2011,57(5):898-902.
[6] Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States?[J].Curr Opin Cardiol,2012,27(4):386-391.
[7] Vemulapalli S, Ard J, Bakris GL, et al. Proceedings from Duke resistant hypertension think tank[J]. Am Heart J,2014,167(6):775-788.
[8] Vega J, Bisognano JD.The prevalence, incidence, prognosis, and associated conditions of resistant hypertension[J]. Seminars Nephrol,2014,34(3):247-256.
[9] 苏万增,李萍,廖峰,等. 难治性高血压135例分析[J]. 中国心血管病研究杂志,2004,2(11):898-899.
[10] Mazzaglia G,Mantovani LG,Sturkenboom MC,et al.Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy:a retrospective cohort study in primary care[J]. J Hypertens,2005,23(11):2093-2100.
[11] Viera AJ. Resistant hypertension[J]. JABFM,2012,25(4):487-495.
[12] Grassi G,Facchini A,Trevano FQ,et al.Obstructive sleep apnea-dependent and independent adrenergic activation in obesity[J]. Hypertension,2005,46(2):321-325.
[13] Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL,et al.Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension[J].Chest,2007,131(2):453-459.
[14] Mosso L, Carvajal C, Gonzalez A,et al.Primary aldosteronism and hypertensive disease[J]. Hypertension,2003,42(2):161-165.
[15] Safian RD,Textor SC.Renal-artery stenosis[J]. N Engl J Med,2001, 344(6):431-442.
[16] Saelen MG, Prosch LK, Gudmundsdottir H,et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function[J]. Blood Press,2005,14(3):170-176.
[17] Calhoun DA, Zaman MA, Nishizaka MK.Resistant hypertension[J].Curr Hypertens Rep,2002,4(3):221-228.
[18] Johnson AG, Nguyen TV, Day RO.Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis[J]. Ann Intern Med,1994,121(4):289-300.
[19] Egan BM, Zhao Y, Axon RN,et al.Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008[J]. Circulation,2011,124(9):1046-1058.
[20] Sacks FM, Svetkey LP, Vollmer WM,et al.Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension(DASH)diet. DASH-Sodium Collaborative Research Group[J]. N Engl J Med,2001,344(1):3-10.
[21] Aucott L, Poobalan A, Smith WC,et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes:a systematic review[J].Hypertension,2005,45(6):1035-1041.
[22] Law MR, Wald NJ, Morris JK,et al.Value of low dose combination treatment with blood pressure lowering drugs:analysis of 354 randomised trials[J]. BMJ,2003,326(7404):1427.
[23] Agarwal R, Sinha AD, Pappas MK,et al.Chlorthalidone for poorly controlled hypertension in chronic kidney disease:an interventional pilot study[J]. Am J Nephrol,2014,39(2):171-182.
[24] de Souza F, Muxfeldt E, Fiszman R,et al.Efficacy of spironolactone therapy in patients with true resistant hypertension[J]. Hypertension,2010,55(1):147-152.
[25] Bisognano JD, Bakris G, Nadim MK,et al.Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial[J]. J Am Coll Cardiol,2011, 58(7):765-773.
[26] Bisognano JD, Kaufman CL, Bach DS,et al.Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system[J]. J Am Coll Cardiol,2011,57(17):1787-1788.
[27] Hoppe UC, Brandt MC, Wachter R,et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial[J]. J Am Soc Hypertens,2012, 6(4):270-276.
[28] Sobotka PA, Mahfoud F, Schlaich MP,et al.Sympatho-renal axis in chronic disease[J]. Clin Res Cardiol,2011,100(12):1049-1057.
[29] Krum H,Schlaich M,Whitbourn R,et al.Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J].Lancet,2009,373(9671):1275-1281.
[30] Symplicity HTNI, Esler MD, Krum H,et al.Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[31] Symplicity HTNI.Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24 months[J]. Hypertension,2011,57(5):911-917.
[32] Bhatt DL, Kandzari DE, O'Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[33] Hering D.Renal denervation superior to drug therapy in hypertension[J].Lancet,2015,38(19981):1922-1924.
相似文献/References:
[1]张宝丽,许建忠,综述,等.副肾动脉与高血压的研究进展[J].心血管病学进展,2016,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.002]
ZHANG Baoli,XU Jianzhong,TANG Xiaofeng,et al.Accessory Renal Artery and Hypertension[J].Advances in Cardiovascular Diseases,2016,(6):224.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.002]
[2]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[3]段兴连,综述,常静,等.阻塞性睡眠呼吸暂停低通气综合征及其干预治疗对心血管疾病的临床意义[J].心血管病学进展,2016,(3):289.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.019]
DUAN Xinglian,CHANG Jing.Clinical Significance of OSAHS and Its Intervention Therapy on
Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):289.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.019]
[4]何平,任洁.C反应蛋白与高血压的关联性研究进展[J].心血管病学进展,2015,(5):596.[doi:10.3969/j.issn.1004-3934.2015.05.018]
HE Ping,REN Jie.Research Progress of C-Reactive Protein and Hypertension[J].Advances in Cardiovascular Diseases,2015,(6):596.[doi:10.3969/j.issn.1004-3934.2015.05.018]
[5]梅宝菲,孔一慧,李为民.睡眠障碍与心血管疾病研究新进展[J].心血管病学进展,2015,(5):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
MEI Baofei,KONG Yihui,LI Weimin.Relationship Between Somnipathy and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(6):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
[6]成哲,罗素新,夏勇.LCZ696在心血管疾病中的研究进展[J].心血管病学进展,2015,(5):606.[doi:10.3969/j.issn.1004-3934.2015.05.021]
CHENG Zhe,LUO Suxin,XIA Yong.Research Progress of LCZ696 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(6):606.[doi:10.3969/j.issn.1004-3934.2015.05.021]
[7]冯颖青.β受体阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):665.[doi:10.3969/j.issn.1004-3934.2015.06.003]
FENG Yingqing.Role of Beta-blocker in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(6):665.[doi:10.3969/j.issn.1004-3934.2015.06.003]
[8]袁静,郭艺芳.利尿剂在降压治疗中的应用[J].心血管病学进展,2015,(6):668.[doi:10.3969/j.issn.1004-3934.2015.06.004]
YUAN Jing,GUO Yifang.Application of Diuretics in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(6):668.[doi:10.3969/j.issn.1004-3934.2015.06.004]
[9]张新军.肾素-血管紧张素系统拮抗剂在高血压治疗中的应用[J].心血管病学进展,2015,(6):673.[doi:10.3969/j.issn.1004-3934.2015.06.005]
ZHANG Xinjun.Effects of Renin-angiotensin System Antagonists on Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2015,(6):673.[doi:10.3969/j.issn.1004-3934.2015.06.005]